Resmed SEC Filings

ResMed (RMD) filed a Form 144 proposing the sale of 100 shares of common stock through Fidelity Brokerage Services with an approximate market value of $27,436, scheduled for 10/01/2025. The shares were acquired by restricted stock vesting on 11/11/2023 and were granted as compensation. The filer previously sold 66 shares on 07/01/2025 for $16,961.34 and 50 shares on 08/01/2025 for $14,095.00. The filing includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.

Form 144 notice for ResMed Inc. (RMD) shows proposed sales of common stock by an individual affiliated with the issuer. The filing lists a broker (Fidelity Brokerage Services) and an intended sale of 3,000 shares with an aggregate market value of $823,080 to be sold on 10/01/2025 on the NYSE. The filer acquired 1,000 shares on 11/11/2022 by restricted stock vesting (compensation) and 2,000 shares on 10/01/2025 via option exercise (options granted 11/14/2018) with cash payment. The form also discloses sales by the same person totaling 9,883 shares in the prior three months with gross proceeds reported for each sale.

Michael J. Farrell, Chief Executive Officer of ResMed Inc. (RMD), reported transactions on Form 4 relating to common stock and stock options. On 09/08/2025 he acquired 8,009 shares at $101.64 per share under a Rule 10b5-1 plan adopted October 31, 2024, and sold 8,009 shares in multiple trades at a weighted-average price of $278.1359 (trade prices ranged $275.27–$279.57). Following the reported transactions his direct beneficial ownership is reported as 475,801 shares after the purchase and 467,792 shares after the sale, with an additional 2,090 shares held indirectly via the Lisette and Michael Farrell Family Trust. He also reports holding 16,020 options exercisable through 11/14/2025; options vest one-third per year.

ResMed Inc. (RMD) Form 144 reports a proposed sale of 8,009 common shares through Fidelity Brokerage Services with an aggregate market value of $2,227,590.84. The filing lists approximately 146,414,839 shares outstanding and an intended sale date of 09/08/2025 on the NYSE.

The shares were acquired under an option granted on 11/14/2018 and shown as acquired on 09/08/2025, with payment in cash. The filer previously sold 8,009 shares on 06/09/2025, 07/07/2025 and 08/07/2025 with gross proceeds of $2,011,909.65, $2,056,076.09 and $2,238,378.55, respectively.

ResMed Inc. (RMD) Form 4: Director Nicole Mowad-Nassar was granted 241 restricted stock units (RSUs) on 09/02/2025. The report shows the award as a non-derivative acquisition and lists 241 shares beneficially owned following the transaction, held in a direct form. The filing explains the RSUs vest on the first anniversary of the grant date. The Form 4 was signed on behalf of Ms. Mowad-Nassar by an attorney-in-fact on 09/03/2025. No price was reported for the grant and no other transactions or derivative positions are disclosed in this filing.

ResMed insider trades on 09/02/2025: Chief Financial Officer Brett Sandercock executed both an acquisition and a sale in ResMed common stock under a Rule 10b5-1 plan. He acquired 2,000 shares at $101.64 per share and sold 3,000 shares at $270.77 per share. Following these transactions his beneficial ownership is reported as 87,745 shares. The 2,000-share purchase reflects option-related activity: a grant of 2,000 options with an exercise price of $101.64 exercisable beginning 11/11/2019 and expiring 11/14/2025; options vest one-third per year. The Form 4 indicates the trades were made pursuant to a 10b5-1 trading plan adopted February 19, 2025.

ResMed insider notice to sell 3,000 common shares via Fidelity on 09/02/2025. The filing reports an aggregate market value of $812,310 for the proposed sale and states the company has 146,414,839 shares outstanding. The shares to be sold were acquired through an options grant (11/14/2018) covering 2,000 shares and restricted stock vesting on 11/11/2022 (204 shares) and 11/18/2022 (796 shares). The filer also disclosed three prior sales over the past three months by Brett Sandercock totaling 7,883 shares for gross proceeds of $2,087,372.17. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.

Justin Leong, Chief Product Officer of ResMed Inc. (RMD), reported that 5,462 shares of company stock were acquired on 08/15/2025 upon the vesting of performance-based restricted stock units. These units were originally granted on 11/20/2024 and were certified as earned by the compensation committee when the performance metrics were met.

Following the transaction, Mr. Leong beneficially owns 27,180 shares. The reported acquisition shows a transaction code of A(1) with a reported price of $0, consistent with earned compensation rather than a market purchase.